An oral medication approved to treat multiple sclerosis (MS) could also put the brakes on inflammation thought to play a role in the development of Alzheimer’s disease, new research suggests.
Successfully passing rounds of expensive and time-consuming clinical trials, the pharmaceutical ponesimod was given the green light to treat MS by the US Food and Drug Administration and European Medicines Agency in 2021.
Now experiments conducted by researchers from the University of Kentucky have produced evidence of the drug blocking overzealous immune activity in the nervous system, which is considered to play a critical role in the onset of dementia.
